- Pain detection app developer PainChek (PCK) has now entered the Canadian market after receiving the tick of approval from Health Canada
- This follows an extended partnership with AlayaCare to use its pain assessment app with the company’s home care software program
- Now it has received the regulatory clearance, AlayaCare will support PainChek as it operates in the Canadian market
- The company expects to begin selling to Canadian clients in the next quarter
- On the market this morning, PainChek is in the grey and trading for 9.2 cents per share
PainChek (PCK) has been approved by Health Canada to sell its pain assessment tool in the North American country.
This approval follows a recent announcement about extending the company’s relationship with Montreal-based healthcare company AlayaCare. Under this agreement, PainChek will integrate its smartphone-based pain assessment and monitoring tool with AlayaCare’s home care software platform.
Now that the regulatory clearance has been received, AlayaCare will provide support to PainChek as it operates in the Canadian market. Notably, the two companies are already working together in Australia.
PainChek is the developer of the world’s first smartphone-based pain assessment and monitoring application. The app detects pain in individuals with moderate-to-severe dementia in aged care facilities and at home.
The company expects to begin selling to Canadian clients in the next quarter.
“We are really pleased to have secured this approval from Health Canada, as it allows us to grow into the sizeable Canadian market with the help of our partner AlayaCare, but also move into aged care services and hospitals in Canada,” CEO Philip Daffas said.
The Canadian market for in-home health and support services alone is worth around C$5 billion (roughly A$5.24 billion).
Earlier this month, the company expanded into the New Zealand market through a partnership with Medi-map.
On the market this morning, PainChek is in the grey and trading for 9.2 cents per share at 11:04 am AEDT.